Cystatin C as a potential biomarker for dosing of renally excreted drugs

British Journal of Clinical Pharmacology

Volumn 80, Issue 1, 2015, Pages 20-27

  Brou, Nguessan Aimé ^c,f   Jacqz Aigrain, Evelyne ^c,d,e   Zhao, Wei ^a,b,c,d,e  

^a THE FIRST AFFILIATED HOSPITAL OF SHANDONG FIRST MEDICAL UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c HÔPITAL ROBERT DEBRÉ   (France)

^d INSERM   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f UNIVERSITÉ FÉLIX HOUPHOUËT BOIGNY   (Côte d’Ivoire)

Author keywords

clearance; cystatin C; dose regimen; glomerular filtration rate; pharmacokinetics; renal elimination; renal function

Indexed keywords

AMIKACIN; CARBOPLATIN; CEFUROXIME; CYSTATIN C; HABEKACIN; TOPOTECAN; VANCOMYCIN; ANTIINFECTIVE AGENT; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; DIGOXIN;

ARTICLE; CREATININE CLEARANCE; CREATININE URINE LEVEL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; HUMAN; IMMUNOASSAY; KIDNEY CLEARANCE; KIDNEY FUNCTION; PREDICTION; PRIORITY JOURNAL; SYSTEMATIC REVIEW; URINARY EXCRETION; KIDNEY FUNCTION TEST; PROCEDURES; URINE;

ANTI-INFECTIVE AGENTS; ANTINEOPLASTIC AGENTS; BIOMARKERS; CYSTATIN C; DIGOXIN; HUMANS; KIDNEY FUNCTION TESTS;

EID: 84933046086     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12602     Document Type: Article

References (61)

1. Chan JC, Williams DM, Roth KS,. Kidney failure in infants and children. Pediatr Rev 2002; 23: 47-60.
2. Ataei N, Bazargani B, Ameli S, Madani A, Javadilarijani F, Moghtaderi M, Abbasi A, Shams S, Ataei F,. Early detection of acute kidney injury by serum cystatin C in critically ill children. Pediatr Nephrol 2014; 29: 133-8.
3. Urakami Y, Kimura N, Okuda M, Masuda S, Katsura T, Inui K,. Transcellular transport of creatinine in renal tubular epithelial cell line LLC-PK1. Drug Metab Pharmacokinet 2005; 20: 200-5.
4. Sansoè G, Ferrari A, Castellana CN, Bonardi L, Villa E, Manenti F,. Cimetidine administration and tubular creatinine secretion in patients with compensated cirrhosis. Clin Sci (Lond) 2002; 102: 91-8.
5. Kemperman FA, Surachno J, Krediet RT, Arisz L,. Cimetidine improves prediction of the glomerular filtration rate by the Cockcroft-Gault formula in renal transplant recipients. Transplantation 2002; 73: 770-4.
6. Branten AJ, Vervoort G, Wetzels JF,. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005; 20: 707-11.
7. Van den Anker JN,. Renal function in preterm infants. Eur J Pediatr 1997; 156: 583-4.
8. Peake M, Whiting M,. Measurement of serum creatinine - current status and future goals. Clin Biochem Rev 2006; 27: 173-84.
9. Rosner MH, Bolton WK,. Renal function testing. Am J Kidney Dis Off J Natl Kidney Found 2006; 47: 174-83.
10. Stevens LA, Levey AS,. Measurement of kidney function. Med Clin North Am 2005; 89: 457-73.
11. Zhao W, Biran V, Jacqz-Aigrain E,. Amikacin maturation model as a marker of renal maturation to predict glomerular filtration rate and vancomycin clearance in neonates. Clin Pharmacokinet 2013; 52: 1127-34.
12. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F,. Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 2002; 91: 13-20.
13. Stevens LA, Coresh J, Greene T, Levey AS,. Assessing kidney function-measured and estimated glomerular filtration rate. N Engl J Med 2006; 354: 2473-83.
14. Coll E, Botey A, Alvarez L, Poch E, Quintõ L, Saurina A, Vera M, Piera C, Darnell A,. Serum cystatin C as a new marker for noninvasive estimation of glomerular filtration rate and as a marker for early renal impairment. Am J Kidney Dis 2000; 36: 29-34.
15. Le Bricon T, Leblanc I, Benlakehal M, Gay-Bellile C, Erlich D, Boudaoud S,. Evaluation of renal function in intensive care: plasma cystatin C vs. creatinine and derived glomerular filtration rate estimates. Clin Chem Lab Med 2005; 43: 953-7.
16. Donadio C, Lucchesi A, Ardini M, Giordani R,. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal 2001; 24: 835-42.
17. Liu J,. Evaluation of serum cystatin C for diagnosis of acute rejection after renal transplantation. Transplant Proc 2012; 44: 1250-3.
18. Cai X, Long Z, Lin L, Feng Y, Zhou N, Mai Q,. Serum cystatin C is an early biomarker for assessment of renal function in burn patients. Clin Chem Lab Med 2012; 50: 667-71.
19. Krishnamurthy N, Arumugasamy K, Anand U, Anand CV, Aruna V, Venu G,. Serum cystatin C levels in renal transplant recipients. Indian J Clin Biochem 2011; 26: 120-4.
20. Kumaresan R, Giri P,. A comparison of serum cystatin C and creatinine with glomerular filtration rate in Indian patients with chronic kidney disease. Oman Med J 2011; 26: 421-5.
21. Yap M, Lamarche J, Peguero A, Courville C,. Serum cystatin C versus serum creatinine in the estimation of glomerular filtration rate in rhabdomyolysis. J Renal Care 2011; 37: 155-7.
22. Abrahamson M, Olafsson I, Palsdottir A, Ulvsbäck M, Lundwall A, Jensson O, Grubb A,. Structure and expression of the human cystatin C gene. Biochem J 1990; 268: 287-94.
23. Tenstad O, Roald AB, Grubb A, Aukland K,. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996; 56: 409-14.
24. Grubb A., Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 1992; 38: 20-7.
25. Randers E, Erlandsen EJ,. Serum cystatin C as an endogenous marker of the renal function-a review. Clin Chem Lab Med 1999; 37: 389-95.
26. Delanaye P, Cavalier E, Morel J, Mehdi M, Maillard N, Claisse G, Lambermont B, Dubois BE, Damas P, Krzesinski J-M, Lautrette A, Mariat C,. Detection of decreased glomerular filtration rate in intensive care units: serum cystatin C versus serum creatinine. BMC Nephrol 2014; 15: 9.
27. Laterza OF, Price CP, Scott MG,. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002; 48: 699-707.
28. Dharnidharka VR, Kwon C, Stevens G,. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.
29. Sh orr AF, Combes A, Kollef MH, Chastre J,. Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy. Crit Care Med 2006; 34: 700-6.
30. Chen Y, Feng J, Li B, Zhang L, Yang Y,. Estimation of safe and effective dose of vancomycin in MRSA-infected patients using serum cystatin C concentrations. Int J Clin Pharmacol Ther 2013; 51: 161-9.
31. Kees MG, Hilpert JW, Gnewuch C, Kees F, Voegeler S,. Clearance of vancomycin during continuous infusion in Intensive Care Unit patients: correlation with measured and estimated creatinine clearance and serum cystatin C. Int J Antimicrob Agents 2010; 36: 545-8.
32. Suzuki A, Imanishi Y, Nakano S, Niwa T, Ohmori T, Shirai K, Yoshida S, Furuta N, Takemura M, Ito H, Ieiri I, Seishima M, Ogura S, Itoh Y,. Usefulness of serum cystatin C to determine the dose of vancomycin in critically ill patients. J Pharm Pharmacol 2010; 62: 901-7.
33. Tanaka A, Aiba T, Otsuka T, Suemaru K, Nishimiya T, Inoue T, Murase M, Kurosaki Y, Araki H,. Population pharmacokinetic analysis of vancomycin using serum cystatin C as a marker of renal function. Antimicrob Agents Chemother 2010; 54: 778-82.
34. Okamoto G, Sakamoto T, Kimura M, Ukishima Y, Sonoda A, Mori N, Kato Y, Maeda T, Kagawa Y,. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem 2007; 40: 485-90.
35. Chung JY, Jin SJ, Yoon JH, Song YG,. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci 2013; 28: 48-54.
36. Halacova M, Kotaska K, Kukacka J, Vavrova V, Kuzelova M, Ticha J, Prusa R,. Serum cystatin C level for better assessment of glomerular filtration rate in cystic fibrosis patients treated by amikacin. J Clin Pharm Ther 2008; 33: 409-17.
37. Viberg A, Lannergård A, Larsson A, Cars O, Karlsson MO, Sandström M,. A population pharmacokinetic model for cefuroxime using cystatin C as a marker of renal function. Br J Clin Pharmacol 2006; 62: 297-303.
38. Otsuka T, Tanaka A, Suemaru K, Inoue T, Nishimiya T, Murase M, Araki H,. Evaluation of the clinical application of cystatin C, a new marker of the glomerular filtration rate, for the initial dose-setting of arbekacin. J Clin Pharm Ther 2008; 33: 227-35.
39. Hoppe A, Séronie-Vivien S, Thomas F, Delord J-P, Malard L, Canal P, Chatelut E,. Serum cystatin C is a better marker of topotecan clearance than serum creatinine. Clin Cancer Res 2005; 11: 3038-44.
40. Schmitt A, Gladieff L, Lansiaux A, Bobin-Dubigeon C, Etienne-Grimaldi M-C, Boisdron-Celle M, Serre-Debauvais F, Pinguet F, Floquet A, Billaud E, Le Guellec C, Penel N, Campone M, Largillier R, Capitain O, Fabbro M, Houede N, Medioni J, Bougnoux P, Lochon I, Chatelut E,. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients. Clin Cancer Res 2009; 15: 3633-9.
41. Hallberg P, Melhus H, Hansson L-O, Larsson A,. Cystatin C vs. creatinine as markers of renal function in patients on digoxin treatment. Ups J Med Sci 2004; 109: 247-53.
42. Garcia A, Hermida J, Tutor JC,. Estimation of the glomerular filtration rate from serum creatinine and cystatin C with regard to therapeutic digoxin monitoring. J Clin Pharmacol 2007; 47: 1450-5.
43. O'Riordan S, Ouldred E, Brice S, Jackson SHD, Swift CG,. Serum cystatin C is not a better marker of creatinine or digoxin clearance than serum creatinine. Br J Clin Pharmacol 2002; 53: 398-402.
44. Matzke GR, Zhanel GG, Guay DR,. Clinical pharmacokinetics of vancomycin. Clin Pharmacokinet 1986; 11: 257-82.
45. Lanao JM, Pedraz JL, Navarro AS, Dominguez-Gil A,. Influence of dose in the urinary excretion of amikacin. Int J Clin Pharmacol 1984; 22: 538-42.
46. Fujii R, Fujita K, Sakata Y, Abe T, Tajima T, Terashima I, Meguro H, Watanabe N, Mikuni K, Sakai T,. [ Clinical studies of arbekacin sulfate in the pediatric field ]. Jpn J Antibiot 1994; 47: 57-83.
47. Foord RD,. Cefuroxime: human pharmacokinetics. Antimicrob Agents Chemother 1976; 9: 741-747.
48. Herben VM, ten Bokkel Huinink WW, Beijnen JH,. Clinical pharmacokinetics of topotecan. Clin Pharmacokinet 1996; 31: 85-102.
49. Gaver RC, Deeb G,. High-performance liquid chromatographic procedures for the analysis of carboplatin in human plasma and urine. Cancer Chemother Pharmacol 1986; 16: 201-6.
50. Hinderling PH, Hartmann D,. Pharmacokinetics of digoxin and main metabolites/derivatives in healthy humans. Ther Drug Monit 1991; 13: 381-401.
51. Zhang PP, Zhan JF, Xie HL, Li LS, Liu ZH,. Evaluation of glomerular filtration rate using cystatin C in diabetic patients analysed by multiple factors including tubular function. J Int Med Res 2010; 38: 473-83.
52. Aksun SA, Ozmen D, Ozmen B, Parildar Z, Mutaf I, Turgan N, Habif S, Kumanlioʇluc K, Bayindir O,. Beta2-microglobulin and cystatin C in type 2 diabetes: assessment of diabetic nephropathy. Exp Clin Endocrinol Diabetes 2004; 112: 195-200.
53. Turnheim K., Drug therapy in the elderly. Exp Gerontol 2004; 39: 1731-8.
54. Tanaka A, Suemaru K, Otsuka T, Ido K, Nishimiya T, Sakai I, Hasegawa H, Inoue T, Murase M, Yasukawa M, Araki H,. Estimation of the initial dose setting of vancomycin therapy with use of cystatin C as a new marker of renal function. Ther Drug Monit 2007; 29: 261-4.
55. Ataei N, Bazargani B, Ameli S, Madani A, Javadilarijani F, Moghtaderi M, Abbasi A, Shams S, Ataei F,. Early detection of acute kidney injury by serum cystatin C in critically ill children. Pediatr Nephrol 2014; 29: 133-8.
56. Beringer PM, Hidayat L, Heed A, Zheng L, Owens H, Benitez D, Rao AP,. GFR estimates using cystatin C are superior to serum creatinine in adult patients with cystic fibrosis. J Cyst Fibros 2009; 8: 19-25.
57. Barnfield MC, Burniston MT, Reid U, Graham AM, Henderson M, Picton SV,. Cystatin C in assessment of glomerular filtration rate in children and young adults suffering from cancer. Nucl Med Commun 2013; 34: 609-14.
58. Tanaka A, Suemaru K, Otsuka T, Ido K, Nishimiya T, Sakai I, Hasegawa H, Yasukawa M, Inoue T, Murase M, Araki H,. Hoek's formula, a cystatin C-based prediction formula for determining the glomerular filtration rate, is the most effective method for original adjusting the dosage of vancomycin. Int J Clin Pharmacol Ther 2007; 45: 592-7.
59. Zhao W, Kaguelidou F, Biran V, Zhang D, Allegaert K, Capparelli EV, Holford N, Kimura T, Lo YL, Peris JE, Thomson A, van den Anker JN, Fakhoury M, Jacqz-Aigrain E,. External evaluation of population pharmacokinetic models of vancomycin in neonates: The transferability of published models to different clinical settings. Br J Clin Pharmacol 2012; 75: 1068-80.
60. Hossain MA, Emara M, El Moselhi H, Shoker A,. Comparing measures of cystatin C in human serum by three methods. Am J Nephrol 2009; 29: 381-91.
61. Thomas F, Séronie-Vivien S, Gladieff L, Dalenc F, Durrand V, Malard L, Lafont T, Poublanc M, Bugat R, Chatelut E,. Cystatin C as a new covariate to predict renal elimination of drugs: application to carboplatin. Clin Pharmacokinet 2005; 44: 1305-16.